CLOS
TPST icon

Compagnie Lombard Odier SCmA’s Tempest Therapeutics TPST Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1
Closed -$5K – 834
2016
Q4 		$5K Hold
1
– – ﹤0.01% 779
2016
Q3 		$24K Hold
1
– – ﹤0.01% 774
2016
Q2 		$18K Hold
1
– – ﹤0.01% 789
2016
Q1 		$32K Hold
1
– – ﹤0.01% 775
2015
Q4 		$33K Buy
+1
New +$33K ﹤0.01% 743

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Compagnie Lombard Odier SCmA's TPST Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 1 share — an estimated $5K sold.

Compagnie Lombard Odier SCmA first reported a position in TPST in Q4 2015 and held it in 5 quarters. The position peaked at $33K in Q4 2015. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

  • Compagnie Lombard Odier SCmA reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1 Tempest Therapeutics share in Q1 2017, an estimated $5K.
  • Compagnie Lombard Odier SCmA first reported a position in Tempest Therapeutics in Q4 2015 and held it in 5 quarters.
  • Compagnie Lombard Odier SCmA's Tempest Therapeutics position peaked at $33K in Q4 2015.
  • 63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.